What are the odds of developing multiple sclerosis?
Evidence quality 4.63/5
Eight-dimension review score against the quality rubric . Each dimension scored 1–5.
- D1 Source grounding
- 5/5
- D2 Source authority
- 5/5
- D3 Arithmetic
- 4/5
- D4 Uncertainty
- 4/5
- D5 Scope
- 5/5
- D6 Prose
- 5/5
- D7 Perception honesty
- 4/5
- D8 Caveat completeness
- 5/5
Lifetime probability · lifetime, global adult
1 in 769
0.1% lifetime chance
Most people underestimate this.
range 1 in 2,000 to 1 in 200
● your factors — click this risk ▾ to reveal
≈ As likely as
Perceived
Multiple sclerosis sits in an odd cultural slot: the name is recognised, the broad picture (progressive, neurological, no cure) is roughly understood, but the actual lifetime odds are almost never the number readers reach for. Most adults, asked to guess, land somewhere between "pretty rare" and "rare enough not to think about". The two features of MS epidemiology that move the number the most — the sharp latitude gradient, and the 2022 finding that essentially every case is preceded by Epstein-Barr virus infection — are barely in the public conversation at all. MS is a fear that is recognised without being calibrated, and the personal odds attached to it drift far from the headline once you adjust for where you live, your sex, and whether you have ever had mono.
Rough estimate: Most adults guess lifetime MS risk well under 1 in 1,000
Source: editorial intuition, not polled
Actual
~2.9 million people living with MS worldwide (35.9 per 100,000)
global adults
Show derivation
Built from two complementary anchors. The Atlas of MS third edition (Walton et al., Mult Scler J, 2020) reports global point prevalence of 35.9 per 100,000 and a pooled incidence rate of 2.1 per 100,000 persons/year across 75 reporting countries. A naive lifetime cumulative incidence is (2.1e-5) × 60 adult years ≈ 1.26e-3, or roughly 1 in 800 global adults. The US population-based estimate from Wallin et al., Neurology 2019 — 309 to 363 per 100,000 point prevalence, equivalent to roughly 850,000 to 1 million Americans — implies a US lifetime incidence closer to 1 in 300 to 1 in 330 once competing mortality and the gap between point prevalence and cumulative incidence are handled. Using the global scope as the headline because US, Scotland, Scandinavia, and northern Canada each sit at ~3x the global average, while tropical and sub-Saharan regions sit well below it; a single global number is only defensible with a wide uncertainty band. Headline 0.0013 (~1 in 770), uncertainty 0.0005 to 0.005 to span the equatorial-to-high-latitude range.
Caveats: The global headline number compresses a very large spread. MS prevalence correla…
The global headline number compresses a very large spread. MS prevalence correlates sharply with latitude — Europe and the Americas sit roughly 3 to 5x above the global mean and the Western Pacific / equatorial regions sit an order of magnitude below — so the single 1-in-770 figure is best read as a midpoint, not a universal baseline. The perceived-vs-actual gap for this fear is not primarily about the headline probability; it is about two reframings that have only recently settled into the epidemiology literature. First, Bjornevik et al. 2022 implies that prior EBV infection is effectively a necessary condition for MS, which changes the disease's status from "unexplained autoimmune" to "late sequel of a common herpesvirus infection". Second, modern disease-modifying therapies have dramatically narrowed the life-expectancy gap between MS patients and the general population — MS in 2026 is not the same disease it was in 1986, even if it is still not curable. This entry is incidence-based, not mortality-based, for that reason: framing MS as "odds of dying from MS" would misrepresent both the disease course and the patient experience under current treatment.
Regional breakdown
The headline figure averages across very different populations. Here’s how the probability varies by geography or context:
| Region / context | Lifetime probability | Notes |
|---|---|---|
| Global average | 1 in 769 |
Walton 2020 global incidence of 2.1 per 100,000 persons/year compounded across adult life |
| US adult | 1 in 333 |
Wallin 2019 US point prevalence ~360 per 100,000 implies lifetime incidence roughly 1 in 300 to 1 in 330; a north-south gradient inside the US persists |
| Scotland, northern Canada, Scandinavia | 1 in 200 |
Highest-prevalence regions globally; consistent with the latitude gradient — MS prevalence scales roughly with distance from the equator |
| Equatorial and tropical regions | 1 in 5,000 |
Western Pacific region reports ~4.8 per 100,000 prevalence in the Atlas of MS — roughly an order of magnitude below the global average |
| Women (global) | 1 in 222 |
Atlas of MS female:male ratio ~2:1 globally; Wallin 2019 US ratio 2.8; women's lifetime incidence sits at roughly 3x the male figure in most cohorts |
| Men (global) | 1 in 667 |
Men's lower lifetime incidence is a real biological gap, not a longevity artefact — MS onset peaks decades before competing mortality matters |
Risks at similar odds
Other risks with roughly the same likelihood — useful for calibration.
COVID-19
What are the odds of dying from COVID-19 over the course of the pandemic and endemic era?
Spinal cord injury
What are the odds of suffering a traumatic spinal cord injury that causes paralysis?
Unsafe imported products
What are the odds of being harmed by an unsafe imported consumer product?
Childhood cancer diagnosis
What are the odds of a child being diagnosed with cancer before age 20?
Counterfeit medicine
What are the odds of being harmed or killed by a counterfeit or substandard medicine?
Recently viewed on this device
Stored locally — clear anytime.
Pick challenger
Roughly 2.9 million people live with multiple sclerosis worldwide according to the MS International Federation’s Atlas of MS, at a global point prevalence of 35.9 per 100,000 and a pooled annual incidence of 2.1 per 100,000 across 75 reporting countries (Walton et al., Mult Scler J, 2020). Compounded across an adult lifetime, that incidence rate works out to roughly 1 in 770 global adults, with the typical diagnosis arriving around age 32. In the United States, Wallin et al. (Neurology, 2019) estimate between 850,000 and 914,000 Americans with MS, a number that roughly doubled the previous conventional figure of ~400,000 once health-claims data replaced the older survey-based estimates. US lifetime incidence is closer to 1 in 300 to 1 in 330 — still uncommon compared to dementia or lung cancer, but an order of magnitude above the global average.
What makes MS unusual in the Likelier catalogue is the size and shape of the heterogeneity around the headline. The latitude gradient is one of the most reproducible findings in neuroepidemiology: Atlas of MS regional prevalence ranges from 4.79 per 100,000 in the Western Pacific to 142.81 per 100,000 in Europe, a roughly 30-fold spread between the low and high extremes. Scotland, northern Canada, and Scandinavia cluster at the top; equatorial regions cluster near the bottom. Women carry roughly 3x the lifetime risk of men, and this gap is real rather than a longevity artefact because MS onset peaks decades before competing mortality matters. The other piece of context the headline number hides: Bjornevik et al. (Science, 2022) followed more than 10 million US military personnel for two decades and found that the hazard ratio for MS after Epstein-Barr virus infection was 32.4, with effectively zero MS cases in the EBV-seronegative subgroup. The current consensus is that prior EBV infection is a likely necessary condition for MS — reframing the disease from “unexplained autoimmune disorder” into “late sequel of a common herpesvirus”.
Where the headline does not apply: almost everywhere, in both directions. A high-latitude woman with a first-degree relative with MS is running a lifetime risk perhaps an order of magnitude above the global mean, while a male adult in an equatorial region with no family history sits well below 1 in 5,000. Two things the probability number also does not capture: modern disease-modifying therapies have dramatically improved the MS life-expectancy gap since the 1990s — MS in 2026 is a genuinely more treatable disease than MS in 1986, even if it is still not curable — and this entry is deliberately framed as incidence, not mortality. Framing MS as “odds of dying from MS” would misrepresent both the clinical course and the patient experience under current treatment. The interesting number is the diagnosis, not the death certificate.
Claim ledger
Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.
-
[1] Walton, King, Rechtman, Kaye, Leray, Marrie, et al. / Multiple Sclerosis Journal (MS International Federation) — Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition
Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition- Statistic
Global MS prevalence 35.9 per 100,000 (2.8 million people); pooled incidence 2.1 per 100,000 persons/year across 75 countries; mean diagnosis age 32 years; female:male prevalence ratio roughly 2:1 globally- Excerpt
“"A total of 2.8 million people are estimated to live with MS worldwide (35.9 per 100,000 population). MS prevalence has increased in every world region since 2013 but gaps in prevalence estimates persist. The pooled incidence rate across 75 reporting countries is 2.1 per 100,000 persons/year, and the mean age of diagnosis is 32 years. Females are twice as likely to live with MS as males." ”
- Source data from
- 2020-12-01
- Accessed
- 2026-04-11 · archived copy
- Calculation
- The Atlas is the only global dataset that reports prevalence, incidence, and sex ratio on a comparable basis across WHO regions. Global lifetime adult incidence ≈ incidence rate × adult years exposed = 2.1e-5 × 60 ≈ 0.00126, which is the normalized headline rounded to 0.0013. Regional prevalence ranges from 4.79 per 100,000 (Western Pacific) to 142.81 per 100,000 (Europe) — roughly a 30-fold spread that the regional_breakdown block below captures. The 2020 figure has since been updated to ~2.9 million in the 2023 Atlas refresh, but the core 35.9/100,000 rate and the 2.1/100,000/year incidence are still the canonical peer-reviewed anchors.
- Independence
- Walton 2020 is the upstream source for nearly every institutional MS prevalence citation (WHO, National MS Society, MSIF member orgs); treat as partially dependent with any Atlas-derived secondary source.
-
[2] Wallin, Culpepper, Campbell, Nelson, Langer-Gould, Marrie, et al. / Neurology (American Academy of Neurology) — The prevalence of MS in the United States: A population-based estimate using health claims data
The prevalence of MS in the United States: A population-based estimate using health claims data- Statistic
US MS prevalence 309.2 per 100,000 (95% CI 308.1-310.1) in 2010, representing 727,344 cases; 2017 projection 337.9 to 362.6 per 100,000 (~850,000 to 914,000 Americans); female:male ratio 2.8; persistent north-south gradient- Excerpt
“"309.2 per 100,000 (95% CI 308.1–310.1), representing 727,344 cases [...] 450.1 per 100,000 (95% CI 448.1–451.6) for women and 159.7 (95% CI 158.7–160.6) for men (female:male ratio 2.8) [...] the prevalence in the northern Census regions of the US (Northeast and Midwest) was statistically significantly higher than in the southern Census region [...] 337.9 per 100,000 population (n = 851,749 persons with MS) to 362.6 per 100,000 population (n = 913,925 persons with MS)." ”
- Source data from
- 2019-02-15
- Accessed
- 2026-04-11 · archived copy
- Calculation
- Wallin 2019 is the methodologically strongest US prevalence estimate — a health-claims-based analysis that roughly doubled the previous conventional figure of ~400,000 Americans with MS to ~900,000+, much of the gap reflecting undercount in earlier methods rather than any real epidemic. The female:male prevalence ratio of 2.8 is the direct source for the ~3:1 sex ratio used in the personal_factor_multipliers block. US lifetime adult incidence implied: ~360 per 100,000 point prevalence with average MS duration ~25-30 years → annual incidence ~12 to 14 per 100,000 → 60-year cumulative ~0.0075, but this overstates lifetime risk because age-specific incidence peaks at 20-40 and is much lower outside that window. The ACS-style cohort-based US lifetime risk figure most commonly cited is ~1 in 300 to 1 in 330, consistent with these numbers. The north-south gradient inside the US is the smaller-scale version of the global latitude effect.
- Independence
- Wallin 2019 and Walton 2020 are methodologically independent (claims data in one country vs international epidemiologic survey) and rely on different upstream datasets, which is why they are paired here.
-
[3] Bjornevik, Cortese, Healy, Kuhle, Mina, Leng, Elledge, Niebuhr, Scher, Munger, Ascherio / Science — Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis
Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis- Statistic
Hazard ratio for MS after EBV infection = 32.4 (95% CI 4.3-245.3); cohort of >10 million US military personnel, 955 MS cases; not elevated after other viral infections (e.g. cytomegalovirus); serum neurofilament light increased only after EBV seroconversion- Excerpt
“"Risk of MS increased 32-fold after infection with EBV but was not increased after infection with other viruses, including the similarly transmitted cytomegalovirus. Serum levels of neurofilament light chain, a biomarker of neuroaxonal degeneration, increased only after EBV seroconversion. These findings cannot be explained by any known risk factor for MS and suggest EBV as the leading cause of MS." ”
- Source data from
- 2022-01-21
- Accessed
- 2026-04-11 · archived copy
- Calculation
- Bjornevik et al. is the primary anchor for the "EBV is likely a necessary cause of MS" framing. The study followed >10 million young adults in the US military over 20 years; of the ~5% who were EBV- negative at baseline, only one of 801 who eventually developed MS remained EBV-negative, and the 32-fold hazard ratio is the direct source for the multiplier value in the personal_factor_multipliers block. The implication for population risk is not a 32x increase in absolute lifetime odds (EBV seroprevalence is ~95% in adults anyway), but rather that the conditional odds given EBV-negative status are near zero. This reframes MS as an infectious-disease sequel rather than a mystery autoimmune disease.
- Independence
- Bjornevik et al. is a primary longitudinal cohort study built on US Department of Defense serum repository samples and DoD MS case ascertainment. Fully independent of the Walton (Atlas of MS) and Wallin (US claims) prevalence pipelines — addresses etiology rather than incidence/prevalence.
-
[4] MS International Federation — Atlas of MS: Number of people with MS
Atlas of MS: Number of people with MS- Statistic
Global MS population grew from 2.3 million in 2013 to 2.8 million in 2020 to 2.9 million in 2023- Excerpt
“"The number of people with MS across the globe has increased from 2.3 million in 2013 to 2.8 million in 2020 and 2.9 in 2023." ”
- Source data from
- 2023-10-01
- Accessed
- 2026-04-11 · archived copy
- Calculation
- Used as the continuously updated headline anchor for the "~2.9 million people living with MS globally" statement. The 2.9M figure is the most recent refresh of the same Atlas methodology that produced the peer- reviewed Walton 2020 paper, so the per-100,000 rate and incidence rate in the primary source remain the quantitative basis; the 2.9M update is used only for the headline count.
- Independence
- Directly downstream from the Walton 2020 peer-reviewed source above; not an independent estimate, just a more recent snapshot of the same data pipeline.